Mr. Michaud joined DNA Capital in 2012 with more than 30 years of investment banking and senior finance executive experience. Over the years, he both advised companies and executed as Chief Financial Officer on several M&A and financing transactions in a variety of sectors including industrials, manufacturing, healthcare, technology and media.
Prior to joining DNA Capital, he held the position of Chief Financial Officer at publicly traded C-Mac Industries, Neurochem, Kangaroo Media, and privately held Groupe Lagassé. Prior to that, he built a career in investment banking at Scotia Capital and TD Securities, where he rose to become Managing Director. Mr. Michaud holds a B.Eng. (civil) from McGill University and an MBA from Cornell University’s Johnson Graduate School of Management. He is a member of the Board of Directors of publicly traded healthcare company TSO3 and the Théatre du Nouveau Monde.